Roy Gulick
机构: Professor of Medicine, Weill Cornell
每年引用次数
引用次数
引用: 25,736
H-指数: 67
I10-指数 : 168
出版物: 298
New antiretroviral drugs
R.M. Gulick
Clinical Microbiology and Infection 9 ( 3) 186 -193
90
2003
Antiretroviral therapy; where are we going?
ROY GULICK
Aids Patient Care and Stds 12 ( 7) 515 -518
1998
AIDS Clinical Trials Group Study A5095 Team. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection
GULICK RM
N Engl J Med 350 ( 18) 1850 -1861
15
2004
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.
Heather J Ribaudo , Catia Marzolini , Todd Hulgan , David B Clifford
AIDS 18 ( 18) 2391 -2400
753
2004
Choosing Initial Antiretroviral Therapy: Current Recommendations for Initial Therapy and Newer or Investigational Agents.
Roy M Gulick
Topics in antiviral medicine 23 ( 4) 128 -131
4
2015
Switching antiretroviral therapy: why, when and how.
Marshall Glesby , Timothy Wilkin , Roy M Gulick
IAPAC monthly 12 ( 7) 220 -229
5
2006
Investigational Antiretroviral Drugs: What is Coming Down the Pipeline.
Roy M Gulick
Topics in antiviral medicine 25 ( 4) 127 -132
11
2018
Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases
Parag Goyal , Roy M Gulick , Michael J Satlin , Khanh Pham
Rheumatology Advances in Practice 5 ( 1)
2021
Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis.
Craig W Hendrix , Krista Yuhas , Mark A Marzinke , Ross D Cranston
AIDS
2021
Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine.
Roy M Gulick , Anne Meibohm , Diane Havlir , Joseph J Eron
AIDS 17 ( 16) 2345 -2349
58
2003
Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study.
Charles Hicks , Martin S King , Roy M Gulick , A Clinton White Jr
AIDS 18 ( 5) 775 -779
109
2004
HIV Entry Inhibitors: Entering the Treatment Paradigm
Roy M Gulick
Retrovirology 2 ( 1) 1 -1
2005
Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353.
Amesika N Nyaku , Lu Zheng , Roy M Gulick , Maxine Olefsky
Journal of Antimicrobial Chemotherapy 74 ( 5) 1376 -1380
10
2019
Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).
Cecilia M Shikuma , Yang Yang , Marshall J Glesby , William A Meyer III
Journal of Acquired Immune Deficiency Syndromes 44 ( 5) 540 -550
46
2007
Antibody 10-1074 suppresses viremia in HIV-1-infected individuals
Marina Caskey , Till Schoofs , Henning Gruell , Allison Settler
Nature Medicine 23 ( 2) 185 -191
242
2017
Racial Disparities in Virologic Failure and Tolerability During Firstline HIV Antiretroviral Therapy.
Priya Bhagwat , Shashi N Kapadia , Heather J Ribaudo , Roy M Gulick
Open Forum Infectious Diseases 6 ( 2)
2
2019
The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies
Golnaz Namazi , Jesse M Fajnzylber , Evgenia Aga , Ronald J Bosch
The Journal of Infectious Diseases 218 ( 12) 1954 -1963
62
2018
Drug Costs: What Can Infectious Diseases Physicians Do?
Shashi N Kapadia , Roy M Gulick
The Journal of Infectious Diseases 221 ( 5) 681 -684
2020
ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL.
Babafemi O Taiwo , Lu Zheng , Andrei Stefanescu , Amesika Nyaku
Clinical Infectious Diseases 66 ( 11) 1689 -1697
52
2018
Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants
Katie R Mollan , Camlin Tierney , Jacklyn N Hellwege , Joseph J Eron
The Journal of Infectious Diseases 216 ( 5) 554 -564
19
2017